Imaging Test for Prostate Cancer Using a New Radioactive Tracer
Tests a new radioactive tracer scan to find prostate cancer in adults.
Plain-language title generated from the registry record
Registry title: 99mTc-QULIC-5-P1 SPECT Imaging in Patients With Prostate Cancer
Key facts
- Where
- Chongqing, ChinaSee the site
- Phase
- Early phase 1
Where in China
- The First Affiliated Hospital of Chongqing Medical UniversityChongqing, ChinaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- First Affiliated Hospital of Chongqing Medical University
- Trial code
- NCT06419348
- Record updated
- 4 June 2025
- Original description
99mTc-QULIC-5-P1 is a new radiotracer targeting PSMA, which is promising as an excellent imaging agent applicable to PSMA positive prostate cancer. This study will investigate the safety, biodistribution and potential usefulness of 99mTc-QULIC-5-P1 SPECT imaging for the diagnosis of lesions in PSMA positive prostate cancer.Read full original descriptionShow less
99mTc-QULIC-5-P1 SPECT Imaging in Patients With Prostate Cancer and Compared With 68Ga-PSMA-11 PET
99mTc-QULIC-5-P1 is a new radiotracer targeting PSMA, which is promising as an excellent imaging agent applicable to PSMA positive prostate cancer. This study will investigate the safety, biodistribution and potential usefulness of 99mTc-QULIC-5-P1 SPECT imaging for the diagnosis of lesions in PSMA positive prostate cancer.
Inclusion: At least 18 years of age; Signed informed consent; Patients with suspected or newly diagnosed or previously prostate cancer, with PSMA positive expression (supporting evidence may include MRI, CT, and pathology report, etc).
Exclusion: Known or expected hypersensitivity to 99mTc-QULIC-5-P1 or any of its components; Any serious medical condition or extenuating circumstance which the investigator feels may interfere with the procedures or evaluations of the study; Patients with PSMA negative expression; Patients with pregnancy; The inability or unwillingness of the research participant, parent or legal representative to provide written informed consent.